HomeCompareCRKT vs JNJ

CRKT vs JNJ: Dividend Comparison 2026

CRKT yields 5714.29% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRKT wins by $228153224412509.56M in total portfolio value
10 years
CRKT
CRKT
● Live price
5714.29%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$228153224412509.59M
Annual income
$220,560,399,839,122,060,000.00
Full CRKT calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CRKT vs JNJ

📍 CRKT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRKTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRKT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRKT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRKT
Annual income on $10K today (after 15% tax)
$485,714.29/yr
After 10yr DRIP, annual income (after tax)
$187,476,339,863,253,750,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CRKT beats the other by $187,476,339,863,253,750,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRKT + JNJ for your $10,000?

CRKT: 50%JNJ: 50%
100% JNJ50/50100% CRKT
Portfolio after 10yr
$114076612206254.81M
Annual income
$110,280,199,919,561,030,000.00/yr
Blended yield
96.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CRKT
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRKT buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRKTJNJ
Forward yield5714.29%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$228153224412509.59M$30.3K
Annual income after 10y$220,560,399,839,122,060,000.00$4,689.40
Total dividends collected$227641622319776.13M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CRKT vs JNJ ($10,000, DRIP)

YearCRKT PortfolioCRKT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$582,129$571,428.57$10,592$272.30+$571.5KCRKT
2$31,711,186$31,088,308.22$11,289$357.73+$31.70MCRKT
3$1,616,661,128$1,582,730,159.44$12,123$472.89+$1616.65MCRKT
4$77,139,944,357$75,410,116,950.20$13,141$629.86+$77139.93MCRKT
5$3,445,379,409,484$3,362,839,669,021.90$14,408$846.81+$3445379.40MCRKT
6$144,058,436,084,716$140,371,880,116,567.28$16,021$1,151.60+$144058436.07MCRKT
7$5,639,412,164,337,400$5,485,269,637,726,755.00$18,122$1,588.22+$5639412164.32MCRKT
8$206,716,597,857,094,600$200,682,426,841,253,570.00$20,930$2,228.20+$206716597857.07MCRKT
9$7,096,097,732,137,874,000$6,874,910,972,430,782,000.00$24,792$3,191.91+$7096097732137.85MCRKT
10$228,153,224,412,509,600,000$220,560,399,839,122,060,000.00$30,274$4,689.40+$228153224412509.56MCRKT

CRKT vs JNJ: Complete Analysis 2026

CRKTStock

Cirmaker Technology Corporation engages in the manufacture, distribution, and assembling of various electronic parts and components for sale primarily in the Asian markets. It provides electronic terminals, electronic blocks and accessories, electronic panel control and locking components, power distribution blocks and accessories, electronic timer and relay sockets, optical fiber connectors and adapters, car audio components, DVD players, electronics, cooling fins and systems for laptop and personal computers, and electrical tools, and other devices. The company also manufactures LCD backlight components and produces voice over Internet Protocol telephones. Further, it distributes or resells crimping tools, switches, cable ties, meters, sirens, power cords, and terminal strips, as well as imports and exports computer chips and various electronic products. Cirmaker Technology Corporation sells its products through sales personnel and marketing agents. The company was organized in 1984 and is based in Taoyuan, Taiwan.

Full CRKT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CRKT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRKT vs SCHDCRKT vs JEPICRKT vs OCRKT vs KOCRKT vs MAINCRKT vs ABBVCRKT vs MRKCRKT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.